Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain

@article{Antoanzas2006CosteffectivenessOM,
  title={Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain},
  author={Fernando Anto{\~n}anzas and Beno{\^i}t Rive and Josep M. Badenas and Susana Gomez-Lus and Chantal Guilhaume},
  journal={The European Journal of Health Economics},
  year={2006},
  volume={7},
  pages={137-144}
}
Several clinical trials have demonstrated the efficacy and safety of the NMDA antagonist memantine in moderately severe to severe Alzheimer’s disease (AD) patients. A 28-week pharmacoeconomic study conducted in the US also showed a reduction of total healthcare costs and informal care compared to placebo. Long-term implications of memantine treatment were modelled in the UK and Finland and revealed reductions in dependency, institutionalization and costs. However, these conclusions were not… CONTINUE READING
9 Citations
43 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Similar Papers

Loading similar papers…